Haemonetics Co. (NYSE:HAE) Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. decreased its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 31.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,532 shares of the medical instruments supplier's stock after selling 15,822 shares during the quarter. Harbor Capital Advisors Inc. owned about 0.07% of Haemonetics worth $2,195,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Thrivent Financial for Lutherans grew its stake in Haemonetics by 14.9% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock valued at $98,716,000 after acquiring an additional 164,111 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Haemonetics by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock valued at $77,470,000 after purchasing an additional 10,990 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in Haemonetics by 0.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 801,049 shares of the medical instruments supplier's stock worth $62,802,000 after buying an additional 5,668 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Haemonetics by 3.2% during the fourth quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock worth $55,575,000 after buying an additional 22,265 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Haemonetics by 16.1% in the 4th quarter. Northern Trust Corp now owns 678,261 shares of the medical instruments supplier's stock valued at $52,959,000 after buying an additional 93,848 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Haemonetics Trading Down 0.3%

Haemonetics stock traded down $0.22 during trading on Thursday, hitting $71.29. The company had a trading volume of 368,555 shares, compared to its average volume of 678,186. The stock has a market cap of $3.42 billion, a price-to-earnings ratio of 28.07, a price-to-earnings-growth ratio of 1.11 and a beta of 0.36. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $94.99. The company's 50 day simple moving average is $64.63 and its 200-day simple moving average is $69.42.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts' consensus estimates of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The company's revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.90 earnings per share. As a group, analysts expect that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HAE. Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. JMP Securities reiterated a "market outperform" rating and issued a $100.00 target price on shares of Haemonetics in a report on Tuesday, May 20th. Needham & Company LLC dropped their price target on shares of Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, Raymond James reaffirmed a "strong-buy" rating and set a $105.00 price target (down previously from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $97.89.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.